Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
More News related to DSCO
- Discovery Laboratories (DSCO) Submits Propsed Protocol for Surfaxin Clinical to U.S. FDA
- Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA
- Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
- Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
- Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
More News related to Earnings
- Mediware (MEDW) to Acquire Healthcare Automation and Advantage Reimbursement for $5.5M
- Dow Chem. (DOW) Subsidiary to Acquire Hyland Seeds; Cowan to Remain General Manager
- Windstream (WIN) to Acquire Iowa Telecom (IWA) for 0.804/Shares Plus $7.90 in Cash; Deal Valued at $1.1B
- Interactive Data Corp. (IDC) to Acquire Dow Jones OFS Data and Tools Assets
- Green Mountain (GMCR) Confirms $32/Share Bid for Diedrich Coffee (DDRX)
Discovery Laboratories (NASDAQ: DSCO) reports Q3 loss of $0.06, even with the analyst estimate of ($0.06).
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
